Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 22Plasma cell 5Other hematologic neoplasm 3Gastrointestinal 3Myeloid 2Lymphoid 2Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Myeloproliferative Disorders 2Venous Thromboembolism 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1

Interventions

Cyclophosphamide 261fludarabine phosphate 233Azacitidine 182fludarabine 181Busulfan 176Cytarabine 155Imatinib Mesylate 152Mycophenolic Acid 148Tacrolimus 146Whole-Body Irradiation 142Peripheral Blood Stem Cell Transplantation 140Cyclosporine 110Antilymphocyte Serum 108Melphalan 107Methotrexate 105Filgrastim 101Decitabine 98nilotinib 94venetoclax 79ruxolitinib 79Dasatinib 68Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 63Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
apixaban × Myeloid × Clear all
NCT04243122 2024-05-29

AIRPORT-MPN

Ottawa Hospital Research Institute

Phase 2 Completed
44 enrolled
Classical hematologyMyeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

NCT04192916 2021-02-21

MPN-DOACs

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Completed
442 enrolled
Myeloid

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡